JonesResearch initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $42 price target The firm says its bullish outlook is driven by denifanstat’s “overlooked potential” in metabolic dysfunction-associated steatohepatitis. A comparative analysis suggests that denifanstat has best-in-disease potential for fibrosis improvement as a GLP-1 combo, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Largest borrow rate increases among liquid names
- Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
- Shopify upgraded, Deere downgaded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 12/6/2024, According to Top Analysts
- Oppenheimer starts Sagimet with Outperform on ‘underappreciated opportunity’